Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

470 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-22

Study Completion Date

2027-08-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infections are a major cause of morbidity and mortality in solid organ transplant recipients. In kidney transplant recipients (KTR) urinary tract infection (UTI) represent 45-72% of all infections, and 30% of all hospitalizations for sepsis. Acute transplant pyelonephritis are the most common complications occurring in more than 20% of patients, mainly in the first year after transplantation. They are associated with an increased risk of acute kidney rejection and long-term kidney graft dysfunction. Gram-negative bacteria, mainly E. coli, account for more than 70% of UTI in KTR. As those infections are favoured by urinary tract modifications/defects and immunosuppression, they are often recurrent and necessitate repeated courses of antibiotics. Selective pressure due to antibiotic consumption, along with frequent hospital admissions and immunosuppression, are well known risk factors for the development of antibiotic resistant infections. Multidrug (MDR)- or extensively (XDR)- drug resistant Enterobacteriaceae including ESBL- or carbapenemase-producing organisms, are thus increasingly observed in transplant units and represent a global threat as very few new antibiotics are expected in the next decade.

One main strategy to limit antimicrobial resistance is to reduce the duration of antibiotic treatment. A 7 day-course is recommended for simple acute pyelonephritis (APN) treated with fluoroquinolones or parenteral B-lactams, prolonged up to 10 or 14 days in the presence of underlying disease at risk of complications. Most KT teams treat patients between 14-21 days as recommended by American guidelines. However, the need to extend treatment duration in immunosuppressed patients is a poorly defined concept and the optimal duration of treatment for APN in KTR is not known as these patients are excluded from most studies.

As there is an urgent need to reduce antibiotic consumption in this population at high risk of developing infections due to resistant pathogens, the hypothesis is that a 7 day-treatment is sufficient to cure APN with good clinical response after 48h of treatment in KTR and is as effective as 14 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized Control Trial of Antibiotic Treatment Duration For Asymptomatic Bacteriuria After Kidney Transplantation

NCT02575495

Kidney Transplantation Bacteriuria Asymptomatic Infections

COMPLETED PHASE2

The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients

NCT02113774

Urinary Tract Infection Bacteriuria Renal Transplantation

UNKNOWN PHASE4

Urinary Tract Infections in Kidney Transplant Recipients

NCT03211026

Kidney Transplantation

UNKNOWN

Study of Pulmonary Infections (Pneumonia) in Kidney Transplant Recipients Admitted to Hospital

NCT05142748

Kidney Transplant Infection

COMPLETED

Duration of Antibiotic Therapy in Acute Kidney Graft Pyelonephritis (AGPN): Effect on the Risk of Recurrence

NCT06848816

Pyelonephritis Acute Kidney Transplantation Recipients

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pyelonephritis Acute Kidney Transplant Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Randomized double blind trial

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

7 day-duration antibiotic treatment

Group Type EXPERIMENTAL

Short antibiotic treatment

Intervention Type DRUG

7 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.

14 day-duration antibiotic treatment

Group Type ACTIVE_COMPARATOR

Usual antibiotic treatment

Intervention Type DRUG

14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Short antibiotic treatment

7 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.

Intervention Type DRUG

Usual antibiotic treatment

14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years KTR
* APN defined by: fever (T°≥38°C) (with or without clinical signs and/or symptoms of UTI) and pyuria (≥10\^4 white blood cells/mL or ≥10/mm3) and positive urine culture (uropathogen ≥10\^3 CFU/mL susceptible to the empirically administrated antibiotic)
* No confirmed or suspected febrile non urinary bacterial infection
* No urologic/renal complication at baseline imaging (abscess, obstruction...)
* Favourable early response to antibiotic treatment:48 to 60 hours after the first dose of antibiotic effective against the causative uropathogen) defined by: T°\<38°C and improvement (or resolution) of signs and/or symptoms of urinary tract infection if present at diagnosis
* Written informed consent

Exclusion Criteria

* Severe or complicated condition

* Any rapidly progressing disease or immediately life-threatening illness, including, but not limited to, septic shock, current or impeding respiratory failure, acute heart or liver failure
* Admission or stay in intensive care unit at baseline
* Obstruction of the urinary tract
* Renal, perinephric or prostatic abscess
* Prior inclusion in this study
* Current participation to another interventional study
* Dual antibiotic therapy (prophylactic antibiotic such as cotrimoxazole allowed) (only 1 dose of aminoside is allowed before randomization)
* First month post transplantation
* Current indwelling catheter (including bladder catheter, ureteral stents, percutaneous nephrostomy tubes)
* Neurogenic bladder
* Enterocystoplasty
* Immunodeficiency or immunosuppressive therapy not related to kidney transplantation including hematologic malignancy, cancer, asplenia, neutropenia\<500 neutrophils/mm3
* Pregnancy, breastfeeding
* Hypersensitivity or previous severe adverse drug reaction to the antibiotic therapy
* Unable or unwilling, in the judgment of the investigator, to comply with the protocol
* Life expectancy\<1 month
* Patient under legal guardianship or without healthcare coverage
* Homeless patient
* Women with childbearing potential not using adequate contraception

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No